Healthcare Industry News: neuromodulation
News Release - July 12, 2010
Neuros Medical Adds Neurostimulation Industry Veteran to Board of DirectorsCLEVELAND--(HSMN NewsFeed)--Neuros Medical, Inc., a medical device company announced today they have added Scott Drees to their Board of Directors. Drees, a seasoned medical device executive with extensive experience in neurostimulation, joins the Neuros Board of Directors as an Independent Board Member.
Drees’ background includes senior level executive positions at Johnson and Johnson, Boston Scientific, St. Jude Medical, and Advanced neuromodulation Systems (ANS). At ANS he led global sales and marketing, growing the company to annual revenues of $144 million. He also was instrumental in the sale of ANS to St. Jude Medical for $1.3 billion in 2005.
“I am excited to be part of such a strong and focused effort at Neuros Medical,” said Drees. “I feel the team, their approach, and technology are targeting a key need in chronic pain, and I look forward to providing value as part of the Board at Neuros.”
“We feel fortunate to have someone of Scott’s expertise, knowledge, and caliber, join the Board of Directors. His addition indicates a strong endorsement of our efforts, and will have substantial impact as we continue to develop a proven treatment for patients with chronic pain, specifically residual limb pain,” said Jon J. Snyder, President and CEO of Neuros Medical.
About Neuros Medical, Inc.
Neuros Medical, a Cleveland, Ohio based neurostimulation company, is focused on developing proprietary neurostimulation therapies for unmet needs to patients worldwide. The company’s patented platform technology, Nerve Block, is focused on the elimination of chronic pain in a variety of applications including neuroma/residual limb pain, chronic post surgical pain, chronic migraine, and trigeminal neuralgia.
Source: Neuros Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.